SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 3149.00 millions for the December 2025 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 4478.30 millions during the year-ago period.The Net Profit of the company vaulted to 360.89% to Rs. 2161.10  millions from Rs. 468.90 millions in the previous quarter.Operating profit for the quarter ended December 2025 decreased to 164.20 millions as compared to 931.40 millions of corresponding quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 3149.00 4478.30 -29.68 10560.50 12744.60 -17.14 17357.00 14421.60 20.35
Other Income 150.30 189.30 -20.60 406.80 347.80 16.96 408.30 303.90 34.35
PBIDT 164.20 931.40 -82.37 755.10 2136.80 -64.66 2947.10 813.00 262.50
Interest 21.00 28.90 -27.34 77.10 60.90 26.60 76.20 104.20 -26.87
PBDT 2898.40 902.50 221.15 3101.80 2075.90 49.42 2910.90 132.70 2093.59
Depreciation 300.20 284.50 5.52 900.60 809.40 11.27 1084.10 1054.50 2.81
PBT 2598.20 618.00 320.42 2201.20 1266.50 73.80 1826.80 -921.80 -298.18
TAX 437.10 149.10 193.16 457.90 149.10 207.11 197.20 0.00 0.00
Deferred Tax 437.10 149.10 193.16 453.50 149.10 204.16 197.20 0.00 0.00
PAT 2161.10 468.90 360.89 1743.30 1117.40 56.01 1629.60 -921.80 -276.78
Equity 140.80 140.80 0.00 140.80 140.80 0.00 140.80 140.80 0.00
PBIDTM(%) 5.21 20.80 -74.93 7.15 16.77 -57.35 16.98 5.64 201.19

Unichem Lab Share Price

337.10 -2.25 (-0.66%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×